IMDX vs PACB

For growth investors, Insight Molecular Diagnostics Inc.

(IMDX) is the stronger pick with 25. 1% revenue growth year-over-year, versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). Analysts rate Insight Molecular Diagnostics Inc. (IMDX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pacific Biosciences of California, Inc.

(PACB) delivered a total return of -93. 4%, compared to -94. 2% for Insight Molecular Diagnostics Inc. (IMDX). Over 10 years, the gap is even starker: PACB returned -81. 3% versus IMDX's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Insight Molecular Diagnostics Inc.

(IMDX) is the lower-risk stock at 1. 18β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 106% more volatile than IMDX relative to the S&P 500.

By revenue growth (latest reported year), Insight Molecular Diagnostics Inc.

(IMDX) is pulling ahead at 25. 1% versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). On earnings-per-share growth, the picture is similar: Insight Molecular Diagnostics Inc. grew EPS -24. 3% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, PACB leads at 7. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pacific Biosciences of California, Inc.

(PACB) is the more profitable company, earning -341. 5% net margin versus -32. 3% for Insight Molecular Diagnostics Inc. — meaning it keeps -341. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PACB leads at -348. 5% versus -32. 5% for IMDX. At the gross margin level — before operating expenses — IMDX leads at 39. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Insight Molecular Diagnostics Inc.

(IMDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 18)). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMDX: -94. 6%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMDX is a small-cap high-growth stock; PACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.